Drug Profile
TST 10088
Alternative Names: TST 88; TST10088Latest Information Update: 28 Feb 2014
Price :
$50
*
At a glance
- Originator Twinstrand Therapeutics
- Developer Emergent BioSolutions
- Class Antineoplastics; Proteins
- Mechanism of Action Apoptosis stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 21 Feb 2014 Cangene Corporation has been acquired and merged into Emergent BioSolutions
- 07 Jul 2009 Twinstrand Therapeutics has been acquired and merged into Cangene-Corporation
- 07 Jul 2009 Twinstrand Therapeutics has been acquired by Cangene Corporation